Fermenta Biotech Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹1,370 Cr
- P/E
- 29.50
- ROE
- 17.34%
- PEG
- 0.44
- Price to sales
- 2.67
- Debt to equity
- 0.26
- 52W high / low
- ₹569 / ₹265
- Sales growth (5Y)
- 6.85%
- EBITDA margin
- 16.19%
- Net profit margin
- 12.45%
- Promoter holding
- 60.12%
- Sales (last year)
- ₹513 Cr
Incorporated in 1951, Fermenta Biotech Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products[1]
Guidance scorecard · Q2 FY27 call
What Fermenta Biotech's management guided
and where it ranks in Pharmaceuticals & Biotechnology
RevenueQ4 FY22 call
10–20%- The company expects about a 20%-25% increase in volumes from capacity expansions, particularly if fully utilized for Vitamin D3, which can significantly boost revenue.
- New product launches like vegan Vitamin D3 and Vitamin K1 are targeted within the next two quarters, which could further drive growth.
- The Saykha plant’s implementation is delayed but will provide additional capacity for new products and minerals, supporting future volume growth.
- The human nutrition segment has grown steadily, with a focus on expanding market share, indicating potential revenue increases in this segment.
2 more points from Fermenta Biotech's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY22 call
FlatSee what Fermenta Biotech said on margins — free account, 30 seconds.
CapexQ4 FY22 call
Planned- Saykha Project: Estimated total investment of Rs. 150 to Rs. 200 crores to be done in phases; currently delayed due to resource availability and strategic decisions.
- Pre-mix Plant: Initiated as a brownfield project in Kullu; plant expected to be commissioned and commercialized by Q4 FY22.
- Multi-purpose Plant Expansion at Dahej: Capacity expansion completed; supports Vitamin D3 and upcoming products like K1 and vegan D3 without additional CAPEX for these products.
- Cautious approach on new CAPEX to avoid over-leveraging; preference to monetize land assets.
- Thane Land: Developing through joint venture Mextech Properties, monetizing via development rights without upfront capital expenditure.
2 more points from Fermenta Biotech's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY22 call
PlannedSee what Fermenta Biotech said on fundraising — free account, 30 seconds.
Order bookQ4 FY22 call
- Q4 FY22 showed increased volumes in human Vitamin D3 (15% growth quarter-on-quarter) and decreased animal feed volumes (64% decline quarter-on-quarter), indicating ongoing demand dynamics.
- The company has focused on catering to the increased Vitamin D3 human nutrition demand during the COVID period.
- New product launches like vegan Vitamin D3 and Vitamin K1 are targeted within the next 2 quarters, potentially contributing to future orders.
- The onboarding of new customers in the human nutrition segment suggests a growing order pipeline.
2 more points from Fermenta Biotech's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Fermenta Biotech latest results (Sep 2026)
Revenue
₹133 Cr
+1.88% YoY
Net profit
₹9 Cr
-48% YoY
Operating margin
15.16%
EPS
₹3.32
Fermenta Biotech shareholding (Sep 2026)
Promoters
60.12%
−3.96 pp QoQ
FIIs
1.05%
+0.92 pp QoQ
DIIs
0.00%
−0.04 pp QoQ
Public
36.43%
+3.24 pp QoQ
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹3,142 Cr | 34.2 | |
| 2 | 40%+ | Up 2%+ | ₹489 Cr | 16.7 | |
| 3 | 40%+ | Up 0–2% | ₹234 Cr | 17.8 | |
| 4 | 40%+ | Flat | ₹18,464 Cr | 1614.0 | |
| 5 | 40%+ | Flat | ₹9,050 Cr | 34.8 | |
| 6 | 40%+ | Flat | ₹4,493 Cr | — |
Sign up free to see every company in the sector ranking and track Fermenta Biotech.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Fermenta Biotech
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Fermenta Biotech
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 62.06% | 62.06% | 62.06% | 62.06% | 62.06% | 64.08% | 64.08% | 64.08% | 64.08% | 64.08% | 64.08% | 60.12% |
| FIIs + | 0.00% | 0.00% | 0.00% | 0.05% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.13% | 1.05% |
| DIIs + | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.04% | 0.00% |
| Public + | 36.05% | 36.05% | 36.11% | 36.41% | 36.98% | 35.00% | 35.00% | 34.75% | 33.99% | 33.32% | 33.19% | 36.43% |
| Others + | 1.89% | 1.89% | 1.82% | 1.47% | 0.94% | 0.89% | 0.89% | 1.14% | 1.90% | 2.58% | 2.55% | 2.39% |
| No. of Shareholders | 15,150 | 15,178 | 14,589 | 13,221 | 12,922 | 12,930 | 12,845 | 13,760 | 14,139 | 13,661 | 14,131 | 16,084 |
Pros & Cons
Fermenta Biotech
Key positives and risks surfaced from the company insights section.
- Promoter holding has decreased over last quarter: -3.96%
- The company has delivered a poor sales growth of 6.85% over past five years.
- Company has a low return on equity of 12.9% over last 3 years.
- Working capital days have increased from 48.7 days to 96.2 days
- Promoter holding has decreased over last quarter: -3.96%
- The company has delivered a poor sales growth of 6.85% over past five years.
- Company has a low return on equity of 12.9% over last 3 years.
- Working capital days have increased from 48.7 days to 96.2 days
Financials of Fermenta Biotech
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 56.91 | 98.97 | 97.34 | 78.13 | 95.03 | 156.47 | 139.85 | 136.26 | 130.22 | 137.36 | 121.58 | 121.82 | 132.67 |
| YoY Sales growth | -41.95% | +80.40% | -7.44% | -5.24% | +66.98% | +58.10% | +43.67% | +74.40% | +37.03% | -12.21% | -13.06% | -10.60% | +1.88% |
| Expenses + | 70.82 | 73.84 | 91.96 | 77.33 | 76.25 | 103.20 | 102.90 | 108.02 | 103.58 | 112.40 | 101.58 | 103.76 | 112.56 |
| Operating Profit | -13.91 | 25.13 | 5.38 | 0.80 | 18.78 | 53.27 | 36.95 | 28.24 | 26.64 | 24.96 | 20.00 | 18.06 | 20.11 |
| OPM % | -24.44% | 25.39% | 5.53% | 1.02% | 19.76% | 34.04% | 26.42% | 20.73% | 20.46% | 18.17% | 16.45% | 14.83% | 15.16% |
| Other Income + | -5.53 | 2.52 | 5.38 | 2.82 | 2.88 | 2.23 | 3.89 | 8.77 | 5.43 | 0.92 | 14.14 | 4.37 | 3.08 |
| Interest | 3.69 | 5.19 | 3.39 | 3.43 | 3.69 | 4.08 | 2.99 | 3.11 | 2.58 | 3.03 | 2.82 | 2.54 | 3.73 |
| Depreciation | 5.93 | 6.38 | 6.46 | 6.12 | 6.15 | 6.08 | 5.86 | 5.81 | 5.41 | 5.37 | 5.11 | 5.20 | 5.21 |
| Profit before tax | -29.06 | 16.08 | 0.91 | -5.93 | 11.82 | 45.34 | 31.99 | 28.09 | 24.08 | 17.48 | 26.21 | 14.69 | 14.25 |
| Tax % | 0.00% | 37.81% | 884.62% | 0.00% | 5.92% | 16.43% | -4.19% | 23.07% | 25.17% | 31.24% | 29.03% | 35.13% | 33.75% |
| Net Profit + | -29.07 | 9.99 | -7.14 | -5.93 | 11.12 | 37.89 | 33.32 | 21.60 | 18.03 | 12.02 | 18.60 | 9.53 | 9.44 |
| EPS in Rs | -9.70 | 3.35 | -2.36 | -1.98 | 3.87 | 12.54 | 11.68 | 7.42 | 6.14 | 4.31 | 6.52 | 3.31 | 3.32 |
Financials of Fermenta Biotech
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 142 | 155 | 164 | 302 | 403 | 292 | 376 | 397 | 349 | 335 | 468 | 523 | 513 |
| Sales growth | +2% | +9% | +6% | +84% | +34% | -28% | +29% | +6% | -12% | -4% | +39% | +12% | -9% |
| Expenses + | 126 | 134 | 152 | 209 | 248 | 225 | 293 | 335 | 330 | 307 | 352 | 422 | 430 |
| Operating Profit | 16 | 21 | 12 | 93 | 156 | 66 | 83 | 62 | 18 | 28 | 115 | 101 | 83 |
| OPM % | 11% | 13% | 7% | 31% | 39% | 23% | 22% | 16% | 5% | 8% | 25% | 19% | 16% |
| Other Income + | 0 | 1 | 3 | 9 | 6 | 12 | 8 | 8 | -20 | 4 | 7 | 29 | 23 |
| Interest | 4 | 6 | 10 | 14 | 21 | 20 | 19 | 18 | 21 | 17 | 15 | 13 | 12 |
| Depreciation | 9 | 8 | 10 | 12 | 12 | 15 | 20 | 26 | 28 | 25 | 24 | 22 | 21 |
| Profit before tax | 3 | 7 | -6 | 76 | 129 | 43 | 52 | 27 | -51 | -10 | 83 | 96 | 73 |
| Tax % | 67% | 61% | 49% | 28% | 8% | -37% | 18% | 44% | 4% | 143% | 8% | 27% | |
| Net Profit + | 1 | 2 | -9 | 46 | 117 | 60 | 43 | 15 | -53 | -24 | 76 | 70 | 50 |
| EPS in Rs | 0.17 | -0.41 | -4.14 | 12.21 | 42.71 | 20.23 | 15.46 | 5.25 | -17.36 | -7.84 | 26.12 | 24.39 | 17.46 |
| Dividend Payout % | 249% | -51% | -5% | 2% | 1% | 24% | 16% | 23% | -7% | -16% | 9% | 15% |
Financials of Fermenta Biotech
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 | 15 | 14 | 14 |
| Reserves | 129 | 128 | 142 | 122 | 246 | 295 | 346 | 358 | 301 | 274 | 348 | 392 | 404 |
| Borrowings + | 71 | 89 | 87 | 173 | 209 | 224 | 232 | 239 | 220 | 139 | 115 | 113 | 109 |
| Other Liabilities + | 60 | 70 | 75 | 87 | 92 | 80 | 94 | 96 | 102 | 120 | 137 | 128 | 169 |
| Total Liabilities | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 648 | 696 |
| Fixed Assets + | 85 | 168 | 172 | 177 | 178 | 200 | 263 | 299 | 267 | 269 | 227 | 220 | 217 |
| CWIP | 65 | 6 | 5 | 4 | 22 | 71 | 57 | 35 | 45 | 2 | 16 | 13 | 23 |
| Investments | 18 | 15 | 18 | 10 | 8 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Other Assets + | 94 | 99 | 112 | 193 | 344 | 342 | 367 | 373 | 321 | 277 | 372 | 414 | 456 |
| Total Assets | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 648 | 696 |
Financials of Fermenta Biotech
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 15 | 4 | 2 | 59 | 90 | 34 | 63 | 43 | 116 | 105 | 41 | 93 |
| Cash from Investing Activity + | -18 | -13 | 7 | -101 | -97 | -44 | -41 | -26 | -55 | -16 | -0 | -43 |
| Cash from Financing Activity + | 1 | 10 | -12 | 89 | 12 | -47 | -1 | -22 | -41 | -91 | -51 | -42 |
| Net Cash Flow | -2 | 1 | -4 | 47 | 6 | -57 | 21 | -4 | 19 | -1 | -10 | 8 |
| Free Cash Flow | -20 | -25 | -17 | 42 | 55 | -34 | 7 | 6 | 76 | 86 | 38 | 63 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 119% | 35% | 35% | 83% | 79% | 73% | 92% | 85% | 610% | 370% | 38% | 108% |
Financials of Fermenta Biotech
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91 | 101 | 99 | 83 | 59 | 87 | 66 | 80 | 44 | 76 | 74 | 78 |
| Inventory Days | 125 | 160 | 208 | 234 | 347 | 594 | 441 | 380 | 309 | 245 | 285 | 290 |
| Days Payable | 95 | 113 | 147 | 183 | 169 | 260 | 169 | 154 | 109 | 182 | 178 | 147 |
| Cash Conversion Cycle | 122 | 148 | 160 | 134 | 237 | 421 | 338 | 306 | 244 | 139 | 181 | 221 |
| Working Capital Days | -61 | -49 | 33 | 54 | 43 | 70 | 54 | 67 | -18 | 9 | 40 | 96 |
| ROCE % | 3% | 6% | 2% | 31% | 41% | 12% | 13% | 7% | -0% | 3% | 23% | 21% |
Guidance history
How Fermenta Biotech's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q4 FY22 call → | 10–20% | Flat | Planned | Planned | — |
| Q3 FY22 call → | 10–20% | Flat | Planned | — | — |
| Q2 FY22 call → | 10–20% | Flat | Planned | — | — |
| Q1 FY22 call → | 10–20% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
86 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,947 stocks |
|---|---|---|
| Last 12 months | +68.2% | 89% |
| Last 6 months | +58.3% | 91% |
| Last 3 months | +2.5% | 68% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,947 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Fermenta Biotech: 0.4 × 89 + 0.4 × 91 + 0.2 × 68 = 86.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 17 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Fermenta Biotech: frequently asked questions
What is Fermenta Biotech share price today?
Fermenta Biotech last traded at ₹465.5, with a market capitalisation of ₹1,370 Cr and a P/E ratio of 29.5.
What were Fermenta Biotech's latest quarterly results?
For the quarter ended Sep 2026, Fermenta Biotech reported revenue of ₹133 Cr (+1.88% year on year) and net profit of ₹9 Cr, with an operating margin of 15.16%.
Is Fermenta Biotech's profit growing?
Net profit was ₹9 Cr in Sep 2026 against ₹18 Cr in Sep 2025, a change of -48%.
What is Fermenta Biotech's EPS?
Fermenta Biotech's earnings per share for the quarter ended Sep 2026 was ₹3.32.
What is the promoter holding in Fermenta Biotech?
Promoters held 60.12% of Fermenta Biotech in Sep 2026 (−3.96 pp versus Jun 2026).
How much do FIIs and DIIs hold in Fermenta Biotech?
In Sep 2026, foreign institutional investors held 1.05% and domestic institutions (including mutual funds) held 0.00% of Fermenta Biotech.
What is Fermenta Biotech's ROE and ROCE?
Fermenta Biotech's return on equity is 17.3% and its return on capital employed is 20.6%.
Does Fermenta Biotech pay a dividend?
Yes. Fermenta Biotech's dividend yield is 0.82% at the current price. The full payout history is on the Fermenta Biotech dividends page.
Which sector does Fermenta Biotech belong to?
Fermenta Biotech is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.
What did Fermenta Biotech's management say on the latest earnings call?
Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Fermenta Biotech's management.
How does Arthneeti AI analyse Fermenta Biotech?
Arthneeti reads Fermenta Biotech's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
